破解Annexin A1介导的化学抵抗的代码
Thanusha Ganesan1, Ajantha Sinniah1, Thamil Selvee Ramasamy2
1Department of Pharmacology, Faculty of Medicine, University Malaya, 50603, Kuala, Lumpur, Malaysia.
Biochemical and biophysical research communications
|June 17, 2024
概括
附件A1 (Anx-A1) 在癌症化学抵抗中起着复杂的作用,影响耐药性和生存途径. 了解Anx-A1为改善癌症治疗结果提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 附录素A1 (Anx-A1),一种超级蛋白质家族,参与各种细胞过程,包括炎症和癌症.
- 它在癌症化学抵抗中的作用是复杂和上下文依赖的,观察到既有抗瘤功能,也有亲瘤功能.
研究的目的:
- 审查Annexin A1 (Anx-A1) 在癌症化学抵抗中的多方面的作用.
- 阐明Anx-A1对关键信号通路的影响及其作为生物标志物和治疗点的潜力.
主要方法:
- 对研究癌症中的Annexin A1 (Anx-A1) 的文献综述.
- 分析Anx-A1参与与化学抵抗相关的途径,包括药物排放,癌症干细胞和上皮-介质酶过渡.
- 探索Anx-A1在生存信号级联中的作用 (PI3K/AKT,MAPK/ERK,NFκ-B).
主要成果:
- 附件A1 (Anx-A1) 呈现出矛盾的作用,以组织特定的方式观察到上下调节.
- 安克斯-A1调节药物外流载体,癌症干细胞种群,DNA损伤和上皮-介质细胞过渡.
- 安克斯-A1影响生存信号通路,并与治疗反应有关.
结论:
- 附件A1 (Anx-A1) 是癌症化学抵抗的一个重要因素,影响了多种癌症特征.
- 安克斯-A1失调对治疗反应有临床影响,并具有作为预后生物标志物的潜力.
- 针对Anx-A1,可能与Ac2-26等药物进行向,为改进癌症疗法提供了有希望的治疗策略.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159


